Literature DB >> 9038264

Hereditary ovarian cancer: molecular genetics and clinical implications.

J Boyd1, S C Rubin.   

Abstract

Epidemiologic data support the existence of two discrete manifestations of hereditary ovarian carcinoma: the breast and ovarian cancer syndrome and the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. Genetic linkage analyses reveal that the majority of breast and ovarian cancer families are linked to the BRCA1 gene, while some cases of hereditary ovarian cancer are also apparent in breast cancer families linked to the BRCA2 gene. The majority of HNPCC families are linked to one of four genes encoding a family of DNA mismatch repair proteins. Molecular analyses demonstrate that genetic screening for germline transmission of a defective allele of one or another of these genes is now possible for high-risk individuals. The ethical, legal, and social implications of this type of analysis are multiple and complex, and genetic counseling requires a thorough understanding of these issues and a cautious approach to most effectively meet the special needs of this patient population. Increased medical surveillance and prophylactic oophorectomy are among the management options that may be appropriate for some genetically predisposed, asymptomatic women. Further research is needed regarding the most effective use of this genetic information in formulating counseling and clinical management strategies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038264     DOI: 10.1006/gyno.1996.4572

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.

Authors:  Jonathan Beesley; Susan J Jordan; Amanda B Spurdle; Honglin Song; Susan J Ramus; Suzanne Kruger Kjaer; Estrid Hogdall; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Paul D P Pharoah; Penelope M Webb; Georgia Chenevix-Trench
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

3.  Information recovery in cancer families: value for risk estimations.

Authors:  Hassan Roudgari; Lindsey F Masson; Neva E Haites
Journal:  Fam Cancer       Date:  2007-05-23       Impact factor: 2.375

4.  Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer.

Authors:  Thomas A Sellers; Yifan Huang; Julie Cunningham; Ellen L Goode; Rebecca Sutphen; Robert A Vierkant; Linda E Kelemen; Zachary S Fredericksen; Mark Liebow; V Shane Pankratz; Lynn C Hartmann; Jeff Myer; Edwin S Iversen; Joellen M Schildkraut; Catherine Phelan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

Review 5.  Genetic testing for inherited breast and ovarian cancer syndromes: important concepts for the primary care physician.

Authors:  M R Taylor
Journal:  Postgrad Med J       Date:  2001-01       Impact factor: 2.401

Review 6.  Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.

Authors:  Tuya Pal; Jenny Permuth-Wey; Ambuj Kumar; Thomas A Sellers
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

7.  Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies.

Authors:  Ting Liu; Lilan Chen; Xiangjun Sun; You Wang; Shu Li; Xia Yin; Xinran Wang; Chenhuan Ding; He Li; Wen Di
Journal:  Tumour Biol       Date:  2013-11-07

8.  Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.

Authors:  Sharon E Johnatty; Jonathan Beesley; Xiaoqing Chen; Amanda B Spurdle; Anna Defazio; Penelope M Webb; Ellen L Goode; David N Rider; Robert A Vierkant; Stephanie Anderson; Anna H Wu; Malcolm Pike; David Van Den Berg; Kirsten Moysich; Roberta Ness; Jennifer Doherty; Mary-Anne Rossing; Celeste Leigh Pearce; Georgia Chenevix-Trench
Journal:  Twin Res Hum Genet       Date:  2009-06       Impact factor: 1.587

9.  Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.

Authors:  A P M Jongsma; J M J Piek; R P Zweemer; R H M Verheijen; J W T Klein Gebbinck; G J van Kamp; I J Jacobs; P Shaw; P J van Diest; P Kenemans
Journal:  Mol Pathol       Date:  2002-10

10.  Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors.

Authors:  M Pedroni; C Di Gregorio; L Cortesi; L Reggiani Bonetti; G Magnani; M L Simone; V Medici; C Priore Oliva; M Marino; M Ponz de Leon
Journal:  Tech Coloproctol       Date:  2013-05-22       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.